B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults
Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate to Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Virologically Suppressed Adults
Sponsor: Gilead Sciences
Terminated
Difficulties enrolling participants
Other terminated trials from Gilead Sciences
Other HIV-1-infection trials with similar outcome
This PHASE4 trial investigates HIV-1-infection and is currently terminated or withdrawn. Gilead Sciences leads this study, which shows 11 recorded versions since 2018 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Sep 2022 — Jan 2023 [monthly]
Terminated PHASE4
Status: Completed → Terminated
-
Jun 2021 — Sep 2022 [monthly]
Completed PHASE4
Status: Recruiting → Completed
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE4
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Feb 2019 — May 2020 [monthly]
Recruiting PHASE4
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE4
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
- University of Alberta
- University of British Columbia
For direct contact, visit the study record on ClinicalTrials.gov .